A European chart review study on early XXXX treatment patterns, clinical outcomes, and healthcare utilization.

@entity1 @entity309
UNASSIGNED: This retrospective medical chart review aimed to provide a current, real-world overview of biologic usage in @entity1 with @entity309 ( @entity309 ) in Germany, Spain, and the UK, and estimate clinical and healthcare utilization outcomes associated with early versus late treatment. Adults (>= 18  years) with a confirmed @entity309 diagnosis between January 2008 and December 2010, who received biologic treatment for >= 3  months and had >= 12  months of follow-up were included. Early treatment was receipt of biologic agent  <=1  year after @entity309 diagnosis. Outcomes included 28-joint disease activity score (DAS28) reduction of >= 1.2 from biologic start and remission (DAS28  <  2.6). Time to outcome was evaluated using Kaplan-Meier curves and log-rank tests. Of 328 @entity1 enrolled (Germany [n  =  111], Spain [n  =  106], UK [n  =  111]), 58.2  % received early biologic (Germany: 55.0  %, UK: 55.9  %, Spain: 64.2  %; p  =  0.321). First-line biologics were more frequent in Spain (26.4  %) and Germany (19.8  %) versus the UK (7.2  %; p  <  0.001). Late-treated @entity1 were hospitalized more often than early-treated @entity1 (10.5 vs 2.9  % [p  =  0.006] for 9.0 vs 5.4 mean inpatient days [p  =  0.408]). DAS28 was 5.1 at biologic initiation (n  =  310); 73.5  % of @entity1 had a DAS28 decrease of >= 1.2 and 44.5  % achieved remission. More @entity1 had DAS28 decrease of >= 1.2 (79.2 vs 65.9  %; p  =  0.009) and remission (51.1 vs 35.6  %; p  =  0.007) with early versus late treatment, with a significant difference in Kaplan-Meier curves when indexing on time since diagnosis (p  <  0.001) and biologic start (p  =  0.024). In @entity309 @entity1 receiving biologic therapy, over half received biologic therapy early. Early initiation was associated with improved clinical outcomes and reduced hospitalization rates versus late treatment.
